These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8830737)

  • 1. Development of a bispecific F(ab')2 conjugate against the complement receptor CR3 of macrophages and a variant CD44 antigen of rat pancreatic adenocarcinoma for redirecting macrophage-mediated tumor cytotoxicity.
    Somasundaram C; Arch R; Matzku S; Zöller M
    Cancer Immunol Immunother; 1996 Jul; 42(6):343-50. PubMed ID: 8830737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-linking tumor cells with effector cells via CD55 with a bispecific mAb induces beta-glucan-dependent CR3-dependent cellular cytotoxicity.
    Gelderman KA; Lam S; Sier CF; Gorter A
    Eur J Immunol; 2006 Apr; 36(4):977-84. PubMed ID: 16525993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a trispecific antibody conjugate that directs two distinct tumor-associated antigens to CD64 on myeloid effector cells.
    Somasundaram C; Sundarapandiyan K; Keler T; Deo YM; Graziano RF
    Hum Antibodies; 1999; 9(1):47-54. PubMed ID: 10331185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical studies comparing different bispecific antibodies for redirecting T cell cytotoxicity to extracellular antigens on prostate carcinomas.
    Lum HE; Miller M; Davol PA; Grabert RC; Davis JB; Lum LG
    Anticancer Res; 2005; 25(1A):43-52. PubMed ID: 15816517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptor and g250: useful target antigens for antibody mediated cellular cytotoxicity against renal cell carcinoma?
    Stadick H; Stockmeyer B; Kühn R; Schrott KM; Kalden JR; Glennie MJ; van de Winkel JG; Gramatzki M; Valerius T; Elsässer D
    J Urol; 2002 Feb; 167(2 Pt 1):707-12. PubMed ID: 11792958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pretargeting for cancer radioimmunotherapy with bispecific antibodies: role of the bispecific antibody's valency for the tumor target antigen.
    Karacay H; Sharkey RM; McBride WJ; Griffiths GL; Qu Z; Chang K; Hansen HJ; Goldenberg DM
    Bioconjug Chem; 2002; 13(5):1054-70. PubMed ID: 12236788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to Fc gamma RI and to HER-2/neu (MDX-210).
    Repp R; Valerius T; Wieland G; Becker W; Steininger H; Deo Y; Helm G; Gramatzki M; Van de Winkel JG; Lang N
    J Hematother; 1995 Oct; 4(5):415-21. PubMed ID: 8581378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3.
    Scheffold C; Kornacker M; Scheffold YC; Contag CH; Negrin RS
    Cancer Res; 2002 Oct; 62(20):5785-91. PubMed ID: 12384539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional relevance of in vivo half antibody exchange of an IgG4 therapeutic antibody-drug conjugate.
    Herbener P; Schönfeld K; König M; Germer M; Przyborski JM; Bernöster K; Schüttrumpf J
    PLoS One; 2018; 13(4):e0195823. PubMed ID: 29672587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor therapy with bispecific antibody: the targeting and triggering steps can be separated employing a CD2-based strategy.
    Wild MK; Strittmatter W; Matzku S; Schraven B; Meuer SC
    J Immunol; 1999 Aug; 163(4):2064-72. PubMed ID: 10438945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A monoclonal antibody against hinge-cleaved IgG restores effector function to proteolytically-inactivated IgGs in vitro and in vivo.
    Brezski RJ; Kinder M; Grugan KD; Soring KL; Carton J; Greenplate AR; Petley T; Capaldi D; Brosnan K; Emmell E; Watson S; Jordan RE
    MAbs; 2014; 6(5):1265-73. PubMed ID: 25517311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody, DF3, and its bispecific antibody.
    Akewanlop C; Watanabe M; Singh B; Walker M; Kufe DW; Hayes DF
    Cancer Res; 2001 May; 61(10):4061-5. PubMed ID: 11358826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma.
    Mazzoni A; Mezzanzanica D; Jung G; Wolf H; Colnaghi MI; Canevari S
    Cancer Res; 1996 Dec; 56(23):5443-9. PubMed ID: 8968099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The enhancement of cytolytic activity in lymphokine activated killer cells using bispecific F(ab')2].
    Azuma A
    Nihon Ika Daigaku Zasshi; 1991 Dec; 58(6):663-72. PubMed ID: 1663120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanisms.
    Link BK; Kostelny SA; Cole MS; Fusselman WP; Tso JY; Weiner GJ
    Int J Cancer; 1998 Jul; 77(2):251-6. PubMed ID: 9650561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Similarities in function between pancreatic tumor cells and macrophages and their inhibition by murine monoclonal antibodies.
    Schorlemmer HU; Bosslet K; Kern HF; Sedlacek HH
    Behring Inst Mitt; 1988 Apr; (82):240-64. PubMed ID: 3408453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The beta-glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells.
    Xia Y; Vetvicka V; Yan J; Hanikýrová M; Mayadas T; Ross GD
    J Immunol; 1999 Feb; 162(4):2281-90. PubMed ID: 9973505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric bispecific OC/TR monoclonal antibody mediates lysis of tumor cells expressing the folate-binding protein (MOv18) and displays decreased immunogenicity in patients.
    Luiten RM; Warnaar SO; Sanborn D; Lamers CH; Bolhuis RL; Litvinov SV; Zurawski VR; Coney LR
    J Immunother; 1997 Nov; 20(6):496-504. PubMed ID: 9409456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal antibody Fab' fragment cross-linking using equilibrium transfer alkylation reagents. A strategy for site-specific conjugation of diagnostic and therapeutic agents with F(ab')2 fragments.
    Wilbur DS; Stray JE; Hamlin DK; Curtis DK; Vessella RL
    Bioconjug Chem; 1994; 5(3):220-35. PubMed ID: 7918742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells.
    Hong F; Hansen RD; Yan J; Allendorf DJ; Baran JT; Ostroff GR; Ross GD
    Cancer Res; 2003 Dec; 63(24):9023-31. PubMed ID: 14695221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.